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The prevalence of epileptic seizures is increased in patients in the clinical stages
of Alzheimer’s disease (AD) when compared to age-matched cognitively normal
populations. In previously reported work from the Presentation of Epileptic Seizures
in Dementia (PrESIDe) study, we identified a clinical suspicion of epilepsy in between
12.75 and 28.43% of patients with AD recruited from a memory clinic. EEGs were not
performed in this study. Patients with epilepsy performed similarly to patients without
epilepsy on cognitive testing at the time of recruitment but were more impaired on
two measures of everyday functioning [Cambridge Behavioral Inventory—Revised and
Clinical Dementia Rating (CBI-R and CDR)]. On repeated testing in this 12-month
follow-up study, patients in whom a suspicion of epilepsy was identified performed
significantly worse on cognitive function testing (p = 0.028) in addition to maintaining
a difference on the informant questionnaires (CBI-R p < 0.001, CDR p = 0.020). These
findings suggest that seizures in this population could be a marker of a more rapid decline
and worse prognosis.
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INTRODUCTION
The prevalence of epileptic seizures is increased in patients in the clinical stages of Alzheimer’s
disease (AD) when compared to age-matched cognitively normal populations (1–3). However,
the extent of this increased risk remains disputed (4–6). Whilst some studies have identified
a risk which is similar to, or only slightly greater than the general population (7, 8); other
studies have identified epileptic seizures in over 50% of AD patients (9, 10). There are several
potential explanation for this divergence, including the means of data collection [retrospective
(11) vs. prospective (12)], the populations being studied [new diagnosis (13) vs. advanced disease
(10)] and the use of supplementary tests [electroencephalography and magnetoencephalography
(14, 15)]. In the Presentation of Epileptic Seizures in Dementia (PrESIDe), 144 patients
were recruited from a regional memory clinic. Participants were interviewed in their own
home in the company of someone who knows them well (an informant). Of this group,
102/144 (70.83%) were diagnosed with AD using recognized diagnostic criteria (16, 17).
Participants were divided into three groups, based on a structured interview (Appendix 1)
administered to the informant, designed to elicit whether any epileptic seizures had occurred
previously: epilepsy probable (E-Pr), epilepsy possible (E-Po), and no clinical evidence of
epilepsy (NCEE) (Table 1). Using this method we identified a clinical suspicion of epilepsy
in 29/102 (28.43%). This included 13/102 (12.75%) in whom it was felt that epilepsy was
probable (E-Pr) and 16/102 (15.69%) in whom it was felt that epilepsy was possible (E-Po).
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TABLE 1 | Seizure group criteria.
Epilepsy probable At least 2 stereotyped episodes suggestive of epilepsy witnessed by a reliable informant
Epilepsy possible Single witnessed episode suggestive of epilepsy, or at least 2 episodes but not both reliably witnessed
No clinical evidence of epilepsy No suspicious episodes reported by patient or informant
Seizure features: altered responsiveness, speech/behavioral arrest, oral/pharyngeal automatism, olfactory/gustatory aura, involuntary movements suggesting focal
motor seizure, other sensory phenomena (including hallucination), amnesia on waking
These findings are comparable to those of recent studies in this
field (14, 15, 18, 19). However, the long-term sequela of epilepsy
in this population remain unclear. Does the presence of epileptic
seizures affect the prognosis in these patients, and if so what is the
nature and extent of this effect?
The aim of this study is to answer these questions through a
12-month follow-up assessment of patients initially recruited to
the PrESIDe study. Our goal was to compare the rate of cognitive
decline in E-Pr, E-Po, and NCEE participants. The initial findings
of the PrESIDe study did not identify a significant difference
in cognitive performance between these groups at the time of
their initial memory clinic assessment or at the time of their
recruitment in to the study. However, there was a difference
in scores on informant completed questionnaires [Cambridge
Behavioral Inventory—Revised and Clinical Dementia Rating
(CBI-R and CDR)] which suggested increased difficulty in
completing activities of daily living (ADLs) and greater care
requirements in patients with dementia who also experienced
epileptic seizures.
METHODS
We recruited patients to the PrESIDe study as outlined previously
(20). Eleven months after their initial study assessment,
participants were contacted via a letter to remind them of the
study and to outline a plan to review them again. Letters were
followed by a telephone call to schedule a follow-up visit. These
interviews were to be performed 12 months (±2 weeks) after
their initial visit, where possible in the same location, at the same
time of day and in the presence of the same informant who was
in attendance for the initial interview.
Assessments consisted of a brief interview to identify whether
any further episodes suggestive of epilepsy had occurred,
or if none had been identified at the time of the first
interview, whether this had changed; as well as brief questioning
to update information on medical history (any changes to
medication, recent illnesses/surgery, etc.) over the intervening
12-months. Subsequently, cognitive testing was repeated using
the Addenbrooke’s Cognitive Examination—Version III (ACE-
III) (Appendix 2). At the same time, the informant was asked to
complete the same two questionnaires (CDR and CBI-R) in order
to compare these with those previously completed.
Between-group analysis of demographic features, cognitive
test performance and informant completed questionnaire scores
was performed using independent sample t-tests and chi-square
testing. Statistical significance was judged as any p-value <0.05.
Adjustments for multiple comparisons were not made as part of
the exploratory analysis of these data. IBM SPSS statistics 22.0
and STATA were used to perform data analysis.
Ethical approval for this project was awarded through the
Integrated Research Application System (IRAS) and provided by
the London—Bromley Research Ethics Committee.
RESULTS
One hundred and two patients with AD were assessed and
included in the initial study. Between the initial visit and the 11-
month mail-out 6 patients had died. From this remaining sample
of 96, the research team was unable to contact 17 patients and 7
patients declined further assessment. This resulted in a total of 72
(70.6%) participants receiving a 12-month follow-up assessment.
The demographic features of the group (n = 72) are
summarized in Table 2 alongside the features of the total
group seen at initial assessment (n = 102) for comparison.
The participants seen for follow-up assessment did not differ
significantly from the total group seen at baseline in terms of
age, gender or ACE-III total score at initial interview. Of these 72
participants, 13 were classified E-Pr, 14 as E-Po [and therefore 27
patient in a combined epilepsy (COMB) group] and 45 as NCEE.
Cognitive Function
At the 12-month follow-up interview the total ACE-III score in
the combined group was significantly lower than in the NCEE
group (p = 0.028) (Table 3). The ACE-III score in the E-Po
group was also significantly lower than the NCEE group at the
12-month follow-up (p = 0.030), whereas the E-Pr group was
not significantly different to the NCEE group (p = 0.177). The
size of the decline between PrESIDE baseline and 12-month
follow-up was significantly greater in the E-Pr, E-Po, and COMB
groups when compared to NCEE. The E-Po, E-Pr, and COMB
groups showed a decline in all domains of the ACE-III test, with
the largest declines seen in the attention, and fluency domains
(Table 4). The declines in all domains in the COMB group were
larger than those of the NCEE group (Figure 1).
Informant Questionnaires
Informant completed questionnaires highlighted significant
differences between the epilepsy and non-epilepsy groups at both
time points (Table 5). The CBI-R scores were significantly greater
for the E-Po, E-Pr, and combined groups at the 12-month interval
[p < 0.001 (E-Po), p = 0.02 (E-Pr), p < 0.001 (COMB)]. The
CDR-SOB (sum of boxes) was significantly greater in the E-Pr
(p = 0.019) and combined groups (p = 0.020) at the time of
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TABLE 2 | Comparing baseline characteristics of total PrESIDe group with group
seen for 12-month follow-up.
Initial PrESIDe
group
(N = 102)
12-month
follow-up
group (N = 72)
Age at baseline (mean, SD) 78.53, 6.47 78.69, 6.77 P = 0.880
Gender (M:F) 51:51 37:35 P = 0.857
ACE-III (at memory clinic) 74.53, 10.53 76.77, 9.25 P = 0.157
ACE-III (at baseline visit) 71.59, 10.86 73.82, 9.92 P = 0.169
Seizure diagnosis:
Probable (E-Pr) 13 (12.75%) 13 (18.06%) P = 0.335
Possible (E-Po) 16 (15.69%) 14 (19.44%) P = 0.520
No clinical Evidence of
Epilepsy (NCEE)
73 (71.57%) 45 (62.50%) P = 0.209
TABLE 3 | ACE-III test scores (mean and S.D) in participants with AD at different
time points, with subjects categorized by suspicion of epilepsy, bold figures
indicate significant difference (p < 0.05) when compared to NCEE group.
Memory clinic PrESIDE
baseline
PrESIDE
12-month
Change
baseline
to 12/12
Total (n = 72) 76.79 (9.25) 73.82 (9.92) 69.56 (12.79) 4.26 (5.81)
NCEE (n = 45) 77.6 (9.7) 74.02 (9.83) 72.11 (11.51) 1.91 (3.69)
E-Po (n = 14) 75 (7.86) 71.79 (10.12) 63.71 (14.82) 8.07 (7.62)
P = 0.365 P = 0.465 P = 0.030 P < 0.001
E-Pr (n = 13) 75.77 (9.31) 75.31 (10.44) 67 (13.14) 8.31 (5.62)
P = 0.548 P = 0.683 P = 0.1773 P < 0.001
Comb (n = 27) 75.38 (8.45) 73.48 (9.31) 65.3 (13.87) 8.19 (6.6)
P = 0.328 P = 0.819 P = 0.028 P < 0.001
their baseline assessments and also at the time of the follow-
up assessments [p = 0.036 (E-Pr), p = 0.05 (COMB)]. On this
measure there was no significant difference between the NCEE
and the E-Po group at either time point [p = 0.179 (baseline),
p = 0.294 (12-month)]. The largest overall change in CDR-SOB
was seen in the E-Pr group (1.21 points) and the smallest change
was seen in the NCEE (0.93 points).
On the CDR, the greatest differences between the combined
E-Pr and E-Po group and the NCEE group were in the judgment
and problem solving domain (0.56 points) and the personal
care domain (0.47 points). The smallest differences were in
the memory (0.10 points) and the orientation (0.11 points)
sections. In contrast, for the CBI-R themost instructive questions
(difference> 1.0) were found to beMemory 5 (Forgets the names
of objects and things), Memory 8 (Becomes confused or muddled
in unusual surroundings), and Sleep 2 (Sleeps more by day than
before). Sleep 2 demonstrated the largest difference between these
groups using the CBI-R (1.60 points) (Table 6). At the time of
their initial PrESIDe assessment, the COMB group performed
significantly worse than the NCEE group on 7/10 CBI-R domains
(skill, care, behavior, mood, belief, eating, sleep). At the 12-month
time point, this increased to 9/10 domains (memory, skill, care,
behavior, belief, eating, sleep, motor, motivation).
Further Seizures
Eight patients reported having further witnessed seizure events
between their initial study visit and their 12-month follow-up
visit. In 3 cases, this occurred in patients who had previously been
classified as E-Po leading to their reclassification as E-Pr. In 1
case, this occurred in patients who had previously been classified
as NCEE. For the purpose of their analysis here they have been
included in their original group. No further generalized onset
tonic-clonic seizures were reported. Most commonly seizures
were focal non-motor onset events involving behavioral arrest,
cognitive, or sensory features. 3/12 patients who experienced
further seizures were described as having motor automatisms
at onset.
Decline in Patients on Anti-epileptic
Medication vs. Those Not on Treatment
4/27 COMB patients had been taking an anti-epileptic
medication between the time of their baseline and 12-month
assessments. In these patients there was a smaller mean decline
in ACE-III scores (−5.75) than in those not taking anti-epileptic
medication (−8.67), which was not significant (p= 0.42).
Dementia Treatments
25/72 patients diagnosed with AD in our cohort (34.7%),
were taking a medication prescribed for the treatment of their
dementia between their baseline and 12-month assessments (18
Donepezil, 5 Rivastigmine, 2 Memantine). Whilst both groups
saw a decrease in their ACE-III scores, this decrease was greater
in the patients taking medication than in those that were not
[−5.36 (SD 6.74) vs. −3.68 (SD 5.24)]. However, this difference
was not significant (p= 0.246).
DISCUSSION
Cognitive Function
Patients with AD and suspected epileptic seizures exhibit an
accelerated decline in cognitive function when compared to
patients with AD in whom there is no clinical suspicion of
epilepsy. This is demonstrated by a fall in the mean ACE-III
score from 74.02 to 72.11 (1.91 points) in the NCEE group
and from 73.48 to 65.30 (8.19 points) in the COMB groups.
Whilst, the NCEE group had a higher ACE-III score at the time
of their initial memory clinic appointment and their baseline
PrESIDe assessment, the difference in scores between this group
and the COMB group only became significant at the time of the
12-month follow-up assessments.
Through, a domain specific analysis of the ACE-III scores we
have shown that a decrease in performance occurs in all domains.
The largest decreases in the epilepsy groups were seen in the
attention, fluency, and memory components of the test. The
difference in the decline between the epilepsy and non-epilepsy
groups was greatest in the attention and fluency elements of
the test. Whilst, all patients with dementia exhibit a decrease
in cognitive function over time, those with epilepsy decline in
a manner which is both greater and involves more domains,
leading to the significant difference across the ACE-III total score.
This supports the view that patients with Alzheimer’s disease who
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TABLE 4 | ACE-III domain scores in AD participants at PrESIDe baseline and 12-month follow-up, bold figures indicate significant difference (p < 0.05) when compared
to NCEE group.
Att Att (2) ± Mem Mem (2) ± Flu Flu (2) ± Lang Lang (2) ± Vis Vis (2) ±
Total 79.6 72.8 −6.8 60.5 54.4 −6 53.1 47.6 −5.5 86.7 85.2 −1.5 85.6 83.4 −2.2
NCEE 79.7 75.9 −3.8 58.9 54.5 −4.5 53.7 52 −1.8 87.6 87.9 0.3 86.8 87.2 0.4
E–Po 76.6 67.1 −9.5 63.5 53.3 −10.2 44.4 36.7 −7.7 84.3 79.7 −4.7 83.5 74.6 −8.9
P = 0.524 P = 0.125 P = 0.384 P = 0.832 P = 0.103 P = 0.010 P = 0.307 P = 0.028 P = 0.481 P = 0.016
E–Pr 82.5 68.4 −14.1 62.4 55.6 −6.8 60.4 44.5 −15.9 86.1 81.7 −4.4 83.7 79.8 −3.8
P = 0.548 P = 0.167 P = 0.516 P = 0.845 P = 0.240 P = 0.209 P = 0.659 P = 0.146 P = 0.514 P = 0.147
Comb 79.4 67.7 −11.7 63 54.4 −8.5 52.1 40.5 −11.6 85.2 80.6 −4.6 83.6 77.1 −6.5
P = 0.938 P = 0.074 P = 0.325 P = 0.982 P = 0.720 P = 0.014 P = 0.350 P = 0.026 P = 0.394 P = 0.016
FIGURE 1 | Comparison of ACE-III total score and sub-domain scores at baseline and 12-month follow-up (COMB vs. NCEE), *indicates significant difference (p <
0.05) when compared to NCEE.
experience epileptic seizures demonstrate a larger, multi-domain,
decline in cognitive function than those without seizures. This is
in contrast to the NCEE group, in whom the largest decline was
seen in thememory domain, with relative stability in the language
and visuospatial domains, and smaller declines in the fluency and
attention domains.
The main question raised by these results is whether epilepsy
is a marker for a more severe form of disease in these patients,
or whether epilepsy is a driver of this more rapid change. The
progression of clinical symptoms in AD is associated with the
spread of the amyloid-β (Aβ) plaques and phosphorylated tau
(p-tau) neurofibrillary tangles into different regions of the brain
(21, 22). Those who experienced epileptic seizures demonstrate
a more rapid decline across all domains. The reasons for this
are not clear, although several studies have investigated the
association between neuronal hyperexcitability and the spread
of tau (23–25), suggesting that seizures can contribute to the
spread of tau through both trans-neuronal (24, 26, 27) and
TABLE 5 | Changes in CDR and CBI-R scores (mean and S.D) in AD participants
between baseline interview and 12-month follow-up, bold figures indicate
significant difference (p < 0.05) when compared to NCEE group.
CDR
baseline
CDR 12-
month
Change CBI-R
baseline
CBI-R 12-
month
Change
Total 4.20 (2.69) 5.20 (3.53) +1.00 38.77 (22.68) 49.16 (25.26) +10.39
NCEE 3.62 (2.46) 4.55 (3.26) +0.93 32.69 (20.47) 40.03 (23.78) +7.34
E-Po 4.67 (2.71) 5.67 (4.05) +1.00 55.00 (25.61) 72.00 (28.00) +17.00
P = 0.179 P = 0.294 P = 0.001 P < 0.001
E-Pr 5.58 (2.98) 6.79 (3.52) +1.21 43.67 (19.74) 57.92 (23.52) +14.25
P = 0.019 P = 0.364 P = 0.092 P = 0.020
Comb 5.13 (2.83) 6.23 (3.76) +1.10 49.09 (22.95) 64.65 (26.17) +15.56
P = 0.020 P = 0.049 P = 0.002 P < 0.001
trans-synaptic (28–30) means. Additionally, studies utilizing tau-
PET have shown a direct correlation between the distribution of
tau and cognitive impairment in patients with dementia (31, 32).
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TABLE 6 | Mean changes in CBI-R domain scores in AD participants between baseline and follow-up assessments (higher scores indicate greater impairment), bold
figures indicate significant difference (p < 0.05) when compared to NCEE group.
Mem1 Mem2 Change Skill1 Skill2 Change Care1 Care2 Change
NCEE 13.3 15.6 +2.3 3.8 5.3 +1.5 0.2 0.8 +0.6
E-Po 14.9 21.0 +6.1 8.1 10.2 +2.1 2.8 3.5 +0.7
P = 0.391 P = 0.008 P = 0.002 P = 0.004 P < 0.001 P = 0.002
E-Pr 16.3 19.7 +3.4 6.4 7.1 +0.8 1.5 2.3 +0.8
P = 0.105 P = 0.033 P = 0.079 P = 0.262 P < 0.001 P = 0.043
Comb 15.6 20.3 +4.7 7.2 8.6 +1.4 2.1 2.9 +0.8
P = 0.114 P = 0.003 P = 0.003 P = 0.014 P < 0.001 P = 0.002
Behav1 Behav2 Change Mood1 Mood2 Change Belief1 Belief2 Change
NCEE 1.8 2.8 +1 2.3 2.6 +0.3 0.1 0.5 +0.4
E-Po 5.6 5.6 0 4.9 3.9 −1 0.9 2.7 +1.8
P < 0.001 P = 0.023 P = 0.001 P = 0.110 P < 0.001 P < 0.001
E-Pr 2.5 3.6 +1.1 3.8 3.7 −0.1 0.6 1.0 +0.4
P = 0.394 P = 0.451 P = 0.040 P = 0.174 P = 0.001 P = 0.244
Comb 4.0 4.6 +0.6 4.3 3.8 −0.5 0.7 1.8 +1.1
P = 0.004 P = 0.049 P = 0.001 P = 0.062 P < 0.001 P = 0.004
Eating1 Eating2 Change Sleep1 Sleep2 Change Motor1 Motor2 Change
NCEE 1.5 1.6 +0.1 2.3 2.5 +0.2 3.4 3.0 −0.4
E-Po 1.7 3.8 +2.1 3.5 5.4 +1.9 4.4 6.0 +1.6
P = 0.798 P = 0.007 P = 0.054 P < 0.001 P = 0.363 P = 0.003
E-Pr 1.9 4.2 +2.3 3.0 4.1 +1.1 3.5 4.3 +0.8
P = 0.618 P = 0.007 P = 0.273 P = 0.017 P = 0.933 P = 0.196
Comb 1.8 4.0 +2.2 3.3 4.7 +1.4 3.9 5.1 +1.2
P = 0.620 P = 0.001 P = 0.043 P < 0.001 P = 0.587 P = 0.012
Motiv1 Motiv2 Change
NCEE 3.9 5.2 +1.3
E-Po 8.1 9.8 +1.7
P = 0.007 P = 0.011
E-Pr 4.3 8.2 +3.9
P = 0.751 P = 0.090
Comb 6.1 9.0 +2.9
P = 0.061 P = 0.007
It is possible that in patients with epileptic seizures the more
rapid decline in cognitive function is related to an accelerated
propagation of tau as a result of their epileptic seizures (33,
34). Conversely, it is also possible that some patients with AD
experience a more aggressive form of this disease and that this
phenotypic heterogeneity also give rise to epileptic seizures in
these patients.
Informant Questionnaires
The E-Pr group scored significantly higher on the CDR-SOB
at the time of their initial study assessment. This difference
persisted and even increased at the 12-month time-point.
Whilst the difference in CDR-SOB at baseline between NCEE
and the COMB groups was 1.51, at follow-up assessment
this had increased to 1.68. Likewise, the CBI-R revealed
roughly twice the decline in the COMB group by comparison
with the NCEE group [7.34 points vs. 15.56 points (p =
0.034)]. These findings again suggest a more rapid accrual of
deficits in these patients, identified by those nearest to them,
and likely to increase their care requirements, and need for
additional support.
Anti-epileptic Treatment
We did not identify a significant difference in cognitive decline
between COMB patients treated with antiepileptic medications
and those that were not. It is possible that the lack of a significant
difference is a result of the small size of these groups, or the
limited duration of follow-up obtained. Other studies looking at
the role of anti-epileptic medication in patients with dementia
and animal models of dementia have reported conflicting
outcomes (35–38). These may be explained by difference in
patient selection, duration of therapy or drug dosage. Further
research is required to define treatment guidelines for epilepsy
occurring in the context of dementia.
Frontiers in Neurology | www.frontiersin.org 5 December 2019 | Volume 10 | Article 1266
Baker et al. Epileptic Seizures in Alzheimer’s Disease
Informal discussion with the clinicians referring into our
study indicated that they were hesitant to prescribe anti-
epileptic medications in patients with MCI and dementia.
Correspondingly, only a small number of patients received
treatment for their epilepsy in our cohort. This hesitation is
partly due to concern about the possible cognitive side effects
of these medications (38–40). Our study was not designed to
interrogate the cognitive effects of anti-epileptic medication
in these patients and further work is required investigate the
potential risk and benefits of the wider use of these medications
in patients with dementia. Multiple trials are currently underway
on this topic (41).
Dementia Treatments
No significant difference was identified in the rate of cognitive
decline in patients with AD taking acetylcholinesterase
inhibitors, or other medications licensed for the treatment
of AD, vs. those that were not. In our cohort there was a
difference between the ACE-III scores at baseline between
these two groups that may explain this (70.75 in treated
group vs. 75.35 in untreated group), although this was
not significant (p = 0.063). There is however extensive
evidence of the beneficial role of acetylcholinesterase
inhibitors in Alzheimer’s disease (42, 43). Our study was
not designed to investigate the role of these medications and
no effort was made to match those on these medications
with those that were not treated at the time of their
baseline assessment.
E-Pr vs. E-Po
At all three time points in our study (memory clinic appointment,
PrESIDe baseline assessment, 12-month follow-up) the two
groups in whom epilepsy was suspected were similar. Whilst
the E-Po group had a lower mean score on the ACE-III at
all time points, the E-Pr group showed the largest decline
from baseline PrESIDe assessment to 12-month follow-up.
However, no significant differences were identified between
them in terms of their ACE-III, CBI-R, or CDR scores at
either baseline or 12-month assessments. This is not wholly
surprising as the only clinical difference between them was
whether or not they had had repeated witnessed episodes
or not.
CONCLUSION
The risk of epilepsy is increased in patients with Alzheimer’s
disease, and in this population a suspicion of epileptic seizures
is associated with an accelerated rate of cognitive decline. This
cognitive decline occurs across all cognitive domains measured
by the ACE-III examination. The difference in the size of the
decline was greatest in the attention and fluency domains of this
test, suggesting that executive function is especially affected in
this population.
Conventional understanding regarding epileptic seizures in
patients with AD suggests that epilepsy occurs as a late-stage
feature, and consequently treating seizures is unlikely to impact
on the progression of disease or to result in any meaningful
functional improvement for these patients. However, the findings
of our study, in keeping with other recent reports (18, 44), suggest
that epileptic seizures occur in patients at early clinical stages of
AD and are associated with accelerated cognitive decline. This
finding should encourage clinicians to identify patients who may
have experienced epileptic seizures following the onset of their
memory impairment and to consider anti-epileptic medication
in these patients, where not contraindicated.
The limitations of our study include the relatively small size
of our cohort, and limited duration of follow-up available. Whilst
only a small number of participants (7/102) declined a follow-
up interview, a larger number (17/102) could not be contacted.
However, this rate of retention is in keeping with similar studies
of this nature (45–47). We used clinical criteria to diagnose
epilepsy. Further investigation would have been of interest. It is
possible that the true incidence of epilepsy among patients with
AD is even higher than we have reported. Several studies looking
at the semiology of seizures in dementia, and AD in particular
have recognized that seizures in this population are more likely
to be focal in onset, often non-motor and rarely generalized
tonic-clonic (18, 48, 49). Such subtle seizures are easily missed.
Several recent studies have looked at the prevalence of subclinical
epileptiform activity in these patients (14, 15, 19). In these studies
prolonged EEG recording, or the use of more in-depth methods
of analysis, such as magnetencephalography have been shown to
identify abnormalities even in the absence of a clinical history
of seizures.
Randomized controlled double-blind studies of the effects of
anti-epileptic medications in appropriately selected patients with
dementia and epilepsy are required in order to evaluate whether
their use can improve the prognosis for patients who suffer from
both conditions.
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